Combination test for COVID-19, influenza A/B, RSV receives FDA 510(k) clearance

News
Article

Previously available under an Emergency Use Authorization, the combination test can detect and distinguish COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The clearance comes ahead of respiratory season, which, according to BD, could result in another “tripledemic” threat.

Combination test for COVID-19, influenza A/B, RSV receives FDA 510(k) clearance | Image Credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com.

Combination test for COVID-19, influenza A/B, RSV receives FDA 510(k) clearance | Image Credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com.

Medical technology company BD (Becton, Dickinson and Company) has announced that the FDA has granted 510(k) clearance for its diagnostic combination test which identifies and differentiates COVID-19, influenza A, influenza B, and respiratory syncytial virus (RSV). According to a press release from BD, the test, BD Respiratory Viral Panel (RVP) for BD MAX System, delivers a result in approximately 2 hours.1

A single nasal swab or nasopharyngeal swab sample is used by the test to determine if a patient has RSV, COVID-19, or influenza A/B. The multi-testing feature allows for increased testing capacity ahead of the fall season, when influenza and RSV seasons generally arrive.1

A 510(k) clearance, or a Premarket Notification, requires device manufacturers to notify the FDA at least 90 days ahead of registration with their intent to market a medical device. This gives the federal agency time to determine if the proposed device is “equivalent” to a device already in 1 of 3 classifications.2

Through an Emergency Use Authorization (EUA) from the FDA, the test has been available since February. According to BD, each BD MAX System is “capable of analyzing hundreds of samples over a 24-hour period.” The test is an RT-PCR assay that makes the distinction between the conditions in approximately 2 hours through the “walkaway workflow” of the BD MAX System, allowing for minimal human interaction.1

References:

  1. BD receives 510(k) clearance for COVID-19, influenza A/B, RSV molecular combination test. BD. Press release. August 1, 2023. Accessed August 3, 2023. https://investors.bd.com/news-releases/news-release-details/bd-receives-510k-clearance-covid-19-influenza-ab-rsv-molecular
  2. 519(k) clearances. FDA. Updated August 31, 2021. Accessed August 3, 2023. https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.